ERBB2 and gastric cancer: While not yet approved for clinical use in gastrointestinal malignancies, margetuximab represents an Fc-optimized mAb targeting HER2 that has demonstrated promising outcomes in HER2-positive solid tumors, notably in gastric cancer [39].